Novartis Deutschland in the news

Novartis shares are experiencing pressure, leading to a dip in the Swiss Market Index, and the document details various composite rating methodologies used for investment analysis.

The article emphasizes the need for Germany to better connect medical research, investment, and healthcare to ensure innovative therapies reach patients, criticizing current policies that hinder this process.

Novartis obtained FDA approval for Rhapsido to treat symptomatic dermographism, expanding its use for chronic hives.

Novartis received FDA approval for Rhapsido (Remibrutinib) to treat symptomatic dermographism, marking the first U.S. approval for this condition.

Novartis expanded its RNA-based therapy portfolio by licensing ABO2203 for autoimmune diseases from Abogen Biosciences, involving an upfront payment and potential milestone payouts.

Goldman Sachs increased Novartis's price target to 113 francs but maintained a 'Sell' rating, with analyst estimates aligning with market consensus and future outlook comments being key.

Deutsche Bank Research maintained a "Hold" rating for Novartis stock with a 120 Swiss Francs price target, based on weekly prescription data.

The Swiss stock market rose, led by strong performances from Novartis and Nestlé, while tech stocks and Roche declined amid geopolitical concerns and tech sector news.

Novartis opened a new office in Munich, making it a key hub and sparking discussions on pharmaceutical innovation, policy challenges, and the need for a more supportive regulatory environment in Germany.

A US federal court dismissed a class-action lawsuit against Novartis, ruling that the company did not unlawfully delay generic competition for its heart failure drug, Entresto.

Goldman Sachs lowered its price target for Novartis to 110 Swiss Francs and maintained its "Sell" rating, citing correction potential compared to the broader pharmaceutical industry.

Deutsche Bank Research maintained its 'Hold' rating for Novartis due to mixed doctor feedback on its BTK and PCSK9 inhibitors, favoring AstraZeneca.

Novartis Deutschland opened a new office in Munich, "The Stack," to enhance collaboration and accelerate medical innovation within the German healthcare landscape.

Novartis' Cosentyx received a positive CHMP opinion for treating giant cell arteritis in adults.

Novartis's Cosentyx received a positive EU recommendation for treating polymyalgia rheumatica, based on a Phase 3 study showing improved symptom relief and reduced corticosteroid use.

Novartis stock reacted to a "Hold" rating from Deutsche Bank, strategic technology acquisitions, and several clinical trial failures, while maintaining its 2026 financial outlook.

Novartis stock closed slightly lower on Xetra on September 17, 2026, underperforming the DAX, despite some positive trends elsewhere and overall market optimism.

Novartis halted the development of its ALS drug VHB937 after it failed a Phase 2 study, contributing to a series of recent clinical setbacks.

Novartis acquired a drug delivery platform from Sironax to enable therapeutics to cross the blood-brain barrier for neurological disease treatments.

Novartis' experimental ALS drug failed a study, and the document details various financial and ESG rating methodologies.